Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 91 articles:
HTML format



Single Articles


    February 2024

  1. Correction to: Estimated Prevalence and Awareness of Hepatitis C Virus Infection Among US Adults: National Health and Nutrition Examination Survey, January 2017-March 2020.
    Clin Infect Dis. 2024 Feb 23:ciad783. doi: 10.1093.
    PubMed    


    January 2024
  2. LITWIN AH, Akiyama MJ
    US Veterans Health Administration Hepatitis C Virus (HCV) Program - A Model for National HCV Elimination though Patient-Centered Medical Homes.
    Clin Infect Dis. 2024 Jan 27:ciae028. doi: 10.1093.
    PubMed    


  3. VARLEY CD, Lowy E, Cartwright EJ, Morgan TR, et al
    Success of the US Veterans Health Administration's Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era.
    Clin Infect Dis. 2024 Jan 27:ciae025. doi: 10.1093.
    PubMed     Abstract available


    November 2023
  4. VINIKOOR MJ, Hamusonde K, Muula G, Asombang M, et al
    Long-term hepatitis B and liver outcomes among adults taking tenofovir-containing antiretroviral therapy for HBV/HIV coinfection in Zambia.
    Clin Infect Dis. 2023 Nov 24:ciad654. doi: 10.1093.
    PubMed     Abstract available


  5. MIDGARD H, Malme KB, Pihl CM, Berg-Pedersen RM, et al
    Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): A stepped wedge cluster randomized trial.
    Clin Infect Dis. 2023 Nov 22:ciad711. doi: 10.1093.
    PubMed     Abstract available


  6. ROWAN SE, Wyles DL
    Don't put off until tomorrow what you can do today: Hospital admissions as an opportunity to treat hepatitis C.
    Clin Infect Dis. 2023 Nov 22:ciad712. doi: 10.1093.
    PubMed    


    October 2023
  7. WONG RJ, Yang Z, Cheung R
    Disparities in Antiviral Treatment among Adults with Hepatitis B Cirrhosis: An Analysis of the National Veterans Affairs Cohort.
    Clin Infect Dis. 2023 Oct 9:ciad617. doi: 10.1093.
    PubMed     Abstract available


    September 2023
  8. YANG J, Lo NC, Dankwa EA, Donnelly CA, et al
    Determining herd immunity thresholds for hepatitis A virus transmission to inform vaccination strategies among people who inject drugs in 16 U.S. States.
    Clin Infect Dis. 2023 Sep 21:ciad552. doi: 10.1093.
    PubMed     Abstract available


    August 2023
  9. TAO Y, Tang W, Fajardo E, Cheng M, et al
    Reflex Hepatitis C Virus Viral Load Testing Following an Initial Positive Hepatitis C Virus Antibody Test: A Global Systematic Review and Meta-analysis.
    Clin Infect Dis. 2023 Aug 31:ciad126. doi: 10.1093.
    PubMed     Abstract available


  10. KAPADIA SN, Jordan AE, Eckhardt BJ, Perlman DC, et al
    The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination.
    Clin Infect Dis. 2023 Aug 27:ciad503. doi: 10.1093.
    PubMed     Abstract available


  11. PETERS MG, Yuen MF, Terrault N, Fry J, et al
    Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes.
    Clin Infect Dis. 2023 Aug 26:ciad506. doi: 10.1093.
    PubMed     Abstract available


  12. HSU CC, Gopalakrishna H, Mironova M, Lee MH, et al
    Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


  13. FELD JJ, Bruneau J, Dore GJ, Ghany MG, et al
    Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


  14. LIANG TJ, Law JLM, Pietschmann T, Ray SC, et al
    Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


  15. BILINSKI A, Slimovitch R, Mendlowitz A, Feld JJ, et al
    First Do No Harm? Modeling Risks and Benefits of Challenge Trials for Hepatitis C Vaccine Development.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


  16. SHOUKRY NH, Cox AL, Walker CM
    Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


  17. LIANG TJ, Feld JJ, Shoukry NH, Thomas DL, et al
    Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Is It Time to Be Real?
    Clin Infect Dis. 2023;77.
    PubMed    


  18. EBERTS JD, Zimmer-Harwood P, Elsey JWB, Fraser-Urquhart A, et al
    Volunteering for Infection: Participant Perspectives on a Hepatitis C Virus Controlled Human Infection Model.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


  19. MARTINELLO M, Naggie S, Rockstroh JK, Matthews GV, et al
    Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


  20. RID A, Feld JJ, Liang TJ, Weijer C, et al
    Ethics of Controlled Human Infection Studies With Hepatitis C Virus.
    Clin Infect Dis. 2023;77.
    PubMed     Abstract available


    July 2023
  21. HOFMEISTER MG, Zhong Y, Moorman AC, Samuel CR, et al
    Temporal trends in hepatitis C-related hospitalizations, United States, 2000-2019.
    Clin Infect Dis. 2023 Jul 18:ciad425. doi: 10.1093.
    PubMed     Abstract available


  22. LEWIS KC, Barker LK, Jiles R, Gupta N, et al
    Estimated prevalence and awareness of hepatitis C virus infection among U.S. adults- National Health and Nutrition Examination Survey, January 2017-March 2020.
    Clin Infect Dis. 2023 Jul 7:ciad411. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  23. BHATTACHARYA D, Aronsohn A, Price J, Lo Re V, et al
    Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Clin Infect Dis. 2023 May 25:ciad319. doi: 10.1093.
    PubMed     Abstract available


    April 2023
  24. DE REZENDE IM, McClure MA, Pereira LS, Fradico JRB, et al
    Characterization and investigation of risk factors for Late-relapsing hepatitis after yellow fever.
    Clin Infect Dis. 2023 Apr 26:ciad249. doi: 10.1093.
    PubMed     Abstract available


  25. GVINJILIA L, Baliashvili D, Shadaker S, Averhoff F, et al
    Impact of HCV infection and treatment on mortality in the country of Georgia, 2015-2020.
    Clin Infect Dis. 2023 Apr 26:ciad182. doi: 10.1093.
    PubMed     Abstract available


  26. LAUTREDOU CC, Dao B, Gounder P
    Epidemiology of Suspected and Confirmed Acute Hepatitis E Cases Reported among Los Angeles County Residents, 2017-2019.
    Clin Infect Dis. 2023 Apr 24:ciad242. doi: 10.1093.
    PubMed     Abstract available


  27. CHEN GJ, Sun HY, Lin KY, Hsieh SM, et al
    A randomized clinical trial of one-dose versus accelerated two-dose schedule for hepatitis A virus revaccination among people with HIV who were non-responders or had seroreversion after primary HAV vaccination.
    Clin Infect Dis. 2023 Apr 10:ciad206. doi: 10.1093.
    PubMed     Abstract available


  28. EDMONDS A, Haley DF, Edwards JK, Ramirez C, et al
    Health Insurance and Initiation of Direct-Acting Antivirals for Hepatitis C in US Women with HIV.
    Clin Infect Dis. 2023 Apr 6:ciad204. doi: 10.1093.
    PubMed     Abstract available


  29. MARKS KM, Kang M, Umbleja T, Avihingsanon A, et al
    Immunogenicity and Safety of Hepatitis B vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People with HIV.
    Clin Infect Dis. 2023 Apr 5:ciad201. doi: 10.1093.
    PubMed     Abstract available


    March 2023
  30. BEISER ME, Shaw LC, Shores SK, Carson JM, et al
    Hepatitis C virus reinfection in a real-world cohort of homeless-experienced individuals in Boston.
    Clin Infect Dis. 2023 Mar 4:ciad127. doi: 10.1093.
    PubMed     Abstract available


    February 2023
  31. GONSALVES GS, Paltiel AD, Thornhill T, DeMaria A, et al
    Patterns of Infectious Disease Associated with Injection Drug Use in Massachusetts.
    Clin Infect Dis. 2023 Feb 9:ciad073. doi: 10.1093.
    PubMed     Abstract available


    January 2023
  32. HERNANDEZ-TAMAYO C, Qato DM, Jewell MP, Gounder P, et al
    COVID-19 Pandemic Associated Declines and Subsequent Increases in Hepatitis C Virus Treatment Prescriptions in Los Angeles County.
    Clin Infect Dis. 2023 Jan 31:ciad050. doi: 10.1093.
    PubMed    


  33. SOWAH LA, Smeaton L, Brates I, Bhattacharya D, et al
    Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
    Clin Infect Dis. 2023 Jan 24:ciad034. doi: 10.1093.
    PubMed     Abstract available


  34. AHRENS K, Sharbaugh M, Jarlenski MP, Tang L, et al
    Prevalence of testing for HIV, HBV, and HCV among Medicaid enrollees treated with medications for opioid use disorder in 11 states, 2016-2019.
    Clin Infect Dis. 2023 Jan 3:ciac981. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  35. POLITI J, Regidor E, Donat M, Pulido J, et al
    Free access to direct-acting antivirals in Spain: more favorable impact on hepatitis C mortality among highly educated people.
    Clin Infect Dis. 2022 Dec 6:ciac928. doi: 10.1093.
    PubMed     Abstract available


    November 2022
  36. THOMAS DL, Kiser JJ, Baum MM
    Long-Acting Treatments for Hepatitis B.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available


  37. OLAGUNJU A, Mathad J, Eke A, Delaney-Moretlwe S, et al
    Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available


  38. THOMAS DL, Owen A, Kiser JJ
    Prospects for Long-Acting Treatments for Hepatitis C.
    Clin Infect Dis. 2022;75.
    PubMed     Abstract available


    October 2022
  39. HOFMANN E, Surial B, Boillat-Blanco N, Gunthard HF, et al
    HBV REPLICATION DURING TENOFOVIR THERAPY IS FREQUENT IN HIV/HBV-COINFECTION.
    Clin Infect Dis. 2022 Oct 15. pii: 6761485. doi: 10.1093.
    PubMed     Abstract available


  40. JACOB JS, Shaikh A, Goli K, Rich NE, et al
    Improved Survival after Liver Transplantation for Patients with HIV and HIV/HCV Coinfection in the INSTI and DAA eras.
    Clin Infect Dis. 2022 Oct 12. pii: 6758523. doi: 10.1093.
    PubMed     Abstract available


    September 2022
  41. BALIASHVILI D, Blumberg HM, Benkeser D, Kempker RR, et al
    Association of treated and untreated chronic hepatitis C with the incidence of active tuberculosis disease: a population-based cohort study.
    Clin Infect Dis. 2022 Sep 22. pii: 6711147. doi: 10.1093.
    PubMed     Abstract available


  42. CHEW KW, Wu K, Tassiopoulos K, Palella FJ, et al
    Liver inflammation is common and linked to metabolic derangements in persons with treated HIV.
    Clin Infect Dis. 2022 Sep 1. pii: 6682837. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  43. MONIN MB, Ingiliz P, Lutz T, Scholten S, et al
    Low spontaneous clearance rates of recently acquired hepatitis C virus in HIV-positive MSM (The PROBE-C Study).
    Clin Infect Dis. 2022 Aug 25. pii: 6675078. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  44. HUDSON AG, Bonacci RA, Moorman AC, Penley M, et al
    Hepatitis C virus infection preceding an outbreak of HIV among persons who inject drugs- Kanawha County, West Virginia, 2019-2021.
    Clin Infect Dis. 2022 Jul 29. pii: 6651445. doi: 10.1093.
    PubMed     Abstract available


  45. HSU HY, Chen HL, Chiang CL, Lai MW, et al
    Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants.
    Clin Infect Dis. 2022 Jul 5. pii: 6629403. doi: 10.1093.
    PubMed     Abstract available


  46. MARATHE G, Moodie EE, Brouillette MJ, Delaunay CL, et al
    Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada.
    Clin Infect Dis. 2022 Jul 5. pii: 6629407. doi: 10.1093.
    PubMed     Abstract available


    May 2022
  47. MAK LY, Cheung KS, Hui RW, Wong DK, et al
    Enhanced liver fibrosis score stratifies hepatocellular carcinoma risk in patients with hepatitis B surface antigen seroclearance.
    Clin Infect Dis. 2022 May 20. pii: 6589789. doi: 10.1093.
    PubMed     Abstract available


  48. CHOW N, Wong D, Lai CL, Mak LY, et al
    Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion.
    Clin Infect Dis. 2022 May 20. pii: 6589784. doi: 10.1093.
    PubMed     Abstract available


  49. WONG RJ, Kaufman HW, Niles JK, Kapoor H, et al
    Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
    Clin Infect Dis. 2022 May 20. pii: 6589786. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  50. JHAVERI R
    Elimination Means Everyone: Targeting Hepatitis C in Infants and Pregnant Patients.
    Clin Infect Dis. 2022 Apr 27. pii: 6574818. doi: 10.1093.
    PubMed    


  51. JOHANNESSON JM, Fridriksdottir RH, Love TJ, Runarsdottir V, et al
    HIGH RATE OF HCV REINFECTION AMONG RECENTLY INJECTING DRUG USERS: RESULTS FROM THE TRAP HEP C PROGRAM - A PROSPECTIVE NATIONWIDE, POPULATION-BASED STUDY.
    Clin Infect Dis. 2022 Apr 19. pii: 6570478. doi: 10.1093.
    PubMed     Abstract available


  52. GROVES J, Dodd RY, Foster GA, Stramer SL, et al
    Genotype Distribution and Demographic Characteristics of Hepatitis C Virus NAT Yield Cases among US Blood Donors.
    Clin Infect Dis. 2022 Apr 11. pii: 6566326. doi: 10.1093.
    PubMed     Abstract available


  53. KUSEJKO K, Salazar-Vizcaya L, Shah C, Stockle M, et al
    Sustained effect on hepatitis C elimination among men who have sex with men in the Swiss HIV Cohort Study: A systematic re-screening for hepatitis C RNA two years following a nation-wide elimination program.
    Clin Infect Dis. 2022 Apr 11. pii: 6566325. doi: 10.1093.
    PubMed     Abstract available


  54. ADES AE, Gordon F, Scott K, Collins IJ, et al
    Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission.
    Clin Infect Dis. 2022 Apr 11. pii: 6566315. doi: 10.1093.
    PubMed     Abstract available


  55. ADES AE, Gordon F, Scott K, Collins IJ, et al
    Spontaneous Clearance Of Vertically Acquired Hepatitis C Infection: Implications For Testing And Treatment.
    Clin Infect Dis. 2022 Apr 9. pii: 6565752. doi: 10.1093.
    PubMed     Abstract available


  56. CARSON JM, Dore GJ, Lloyd AR, Grebely J, et al
    Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study.
    Clin Infect Dis. 2022 Apr 1. pii: 6562011. doi: 10.1093.
    PubMed     Abstract available


    March 2022
  57. AMIN J, Vaccher S, Templeton DJ, Bavinton B B, et al
    Low prior exposure and incidence of hepatitis C in HIV negative gay and bisexual men taking PrEP: findings from the EPIC-NSW prospective implementation study.
    Clin Infect Dis. 2022 Mar 30. pii: 6555792. doi: 10.1093.
    PubMed     Abstract available


  58. LEE TH, Hunt CM, Maier MM, Lowy E, et al
    Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study.
    Clin Infect Dis. 2022 Mar 29. pii: 6555659. doi: 10.1093.
    PubMed     Abstract available


  59. MOUTCHIA J, Njouom R, Rumpler E, Besombes C, et al
    Maternal Age at First Childbirth and Geographical Variation in Hepatitis B Virus Prevalence in Cameroon: Important Role of Mother-to-Child Transmission.
    Clin Infect Dis. 2022;74:836-845.
    PubMed     Abstract available


  60. HOENIGL M, Abramovitz D, Flores Ortega RE, Martin NK, et al
    Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States.
    Clin Infect Dis. 2022 Mar 2. pii: 6540915. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  61. TRICKEY A, Croxford S, Emanuel E, Ijaz S, et al
    The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in England, Wales, and Northern Ireland.
    Clin Infect Dis. 2022 Feb 20. pii: 6532589. doi: 10.1093.
    PubMed     Abstract available


  62. TESHALE EH, Roberts H, Gupta N, Jiles R, et al
    Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014-2020.
    Clin Infect Dis. 2022 Feb 16. pii: 6529537. doi: 10.1093.
    PubMed     Abstract available


  63. GORDON SC, Teshale EH, Spradling PR, Moorman AC, et al
    Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018).
    Clin Infect Dis. 2022 Feb 11. pii: 6526938. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  64. HUANG YC, Sun HY, Sheng WH, Hsieh SM, et al
    Evolution of hepatitis B virus (HBV) serologic markers among antiretroviral-naive, young people living with HIV who had undergone neonatal HBV vaccination and initiated antiretroviral therapy.
    Clin Infect Dis. 2021 Dec 10. pii: 6459150. doi: 10.1093/cid/ciab1020.
    PubMed     Abstract available


  65. LIU CJ, Sheen IS, Chen CY, Chuang WL, et al
    Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment.
    Clin Infect Dis. 2021 Dec 2. pii: 6448442. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  66. LIU S, Deng R, Zhou B, Sun J, et al
    Is the World Health Organization Hepatitis B Virus (HBV) DNA Standard Appropriate for Standardizing Serum HBV RNA Assays?
    Clin Infect Dis. 2021;73:e2821-e2823.
    PubMed    


  67. WORETA TA, Chalasani N
    Fatty Liver Disease in Human Immunodeficiency Virus-Hepatitis B Virus Coinfection: A Cause for Concern.
    Clin Infect Dis. 2021;73:e3286-e3287.
    PubMed    


  68. LEE JH, Lee YB, Cho EJ, Yu SJ, et al
    Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study.
    Clin Infect Dis. 2021;73:e3308-e3316.
    PubMed     Abstract available


    October 2021
  69. SRIDHAR S, Yip CC, Lo KH, Wu S, et al
    Hepatitis E virus species C infection in humans, Hong Kong.
    Clin Infect Dis. 2021 Oct 27. pii: 6412704. doi: 10.1093.
    PubMed     Abstract available


  70. WELD ED, Astemborski J, Kirk GD, Sulkowski MS, et al
    Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments.
    Clin Infect Dis. 2021 Oct 26. pii: 6410743. doi: 10.1093.
    PubMed     Abstract available


  71. KHALILI M, King WC, Kleiner DE, Chung RT, et al
    Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.
    Clin Infect Dis. 2021 Oct 25. pii: 6410628. doi: 10.1093.
    PubMed     Abstract available


  72. HARNEY BL, Sacks-Davis R, van Santen DK, Traeger M, et al
    The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.
    Clin Infect Dis. 2021 Oct 25. pii: 6410633. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  73. BAROCAS JA, Savinkina A, Lodi S, Epstein RL, et al
    Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study.
    Clin Infect Dis. 2021 Sep 9. pii: 6367757. doi: 10.1093.
    PubMed     Abstract available


  74. GAO Y, Kong F, Song X, Shang J, et al
    Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial.
    Clin Infect Dis. 2021 Sep 6. pii: 6364928. doi: 10.1093.
    PubMed     Abstract available


    August 2021
  75. TULLY DC, Hahn JA, Bean DJ, Evans JL, et al
    Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships.
    Clin Infect Dis. 2021 Aug 27. pii: 6358610. doi: 10.1093.
    PubMed     Abstract available


  76. LIU L, Wang L, Zhang H, Ou W, et al
    Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus-Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys.
    Clin Infect Dis. 2021;73:642-649.
    PubMed     Abstract available


    July 2021
  77. GORMLEY MA, Akiyama MJ, Rennert L, Howard KA, et al
    Changes in health-related quality of life for HCV-infected people who inject drugs on opioid agonist treatment following sustained virologic response.
    Clin Infect Dis. 2021 Jul 31. pii: 6332893. doi: 10.1093.
    PubMed     Abstract available


  78. IJAZ S, Derrick J, Shute J, Ireland G, et al
    Mother To Infant Transmission Of Hepatitis B Virus In The Face Of Neonatal Immunisation Is Not Necessarily Primary Vaccine Failure.
    Clin Infect Dis. 2021 Jul 12. pii: 6319332. doi: 10.1093.
    PubMed     Abstract available


  79. DEZANET LNC, Kassime R, Miailhes P, Lascoux-Combe C, et al
    Effect of viral replication and liver fibrosis on all-cause mortality in HIV/HBV coinfected individuals: a retrospective analysis of a 15-year longitudinal cohort.
    Clin Infect Dis. 2021 Jul 1. pii: 6312684. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  80. BARTLETT SR, Wong S, Yu A, Pearce M, et al
    The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study.
    Clin Infect Dis. 2021 Jun 14. pii: 6298569. doi: 10.1093.
    PubMed     Abstract available


  81. VALERIO H, Alavi M, Law M, McManus H, et al
    Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study.
    Clin Infect Dis. 2021 Jun 9. pii: 6295650. doi: 10.1093.
    PubMed     Abstract available


  82. ONOFRIO FQ, Cooper C, Borgia SM, Vachon ML, et al
    Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
    Clin Infect Dis. 2021;72:e799-e805.
    PubMed     Abstract available


    May 2021
  83. BOEKE CE, Hiebert L, Waked I, Tsertsvadze T, et al
    Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low- and Middle-Income Countries.
    Clin Infect Dis. 2021 May 20. pii: 6279051. doi: 10.1093.
    PubMed     Abstract available


  84. TOY M, Hutton D, Harris AM, Nelson N, et al
    Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Clin Infect Dis. 2021 May 6. pii: 6270943. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  85. HEO M, Pericot-Valverde I, Rennert L, Akiyama MJ, et al
    Hepatitis C virus DAA treatment adherence patterns and SVR among people who inject drugs treated in opioid agonist therapy programs.
    Clin Infect Dis. 2021 Apr 20. pii: 6238636. doi: 10.1093.
    PubMed     Abstract available


  86. MERAT S, Sharifi AH, Poustchi H, Hajiani E, et al
    Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial.
    Clin Infect Dis. 2021 Apr 15. pii: 6226813. doi: 10.1093/cid/ciaa1768.
    PubMed    


  87. LEE SK, Sung PS, Park SS, Min CK, et al
    Reactivation of resolved hepatitis B after daratumumab for multiple myeloma.
    Clin Infect Dis. 2021 Apr 13. pii: 6224403. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  88. ZHANG H, Wang F, Zhu X, Chen Y, et al
    Antiviral Activity and Pharmacokinetics of the HBV Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection.
    Clin Infect Dis. 2020 Jul 10. pii: 5869864. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  89. CHANCHAROENTHANA W, Leelahavanichkul A
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Benefits and Risks.
    Clin Infect Dis. 2020 Jun 3. pii: 5850914. doi: 10.1093.
    PubMed    


    February 2020
  90. WANG XD, Liu JP, Song TR, Huang ZL, et al
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Clinical Outcomes at a High-volume Center in China.
    Clin Infect Dis. 2020 Feb 26. pii: 5758069. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  91. BOGLIONE L, Lipani F, Lucchini AM, Salvador E, et al
    Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue.
    Clin Infect Dis. 2019 Dec 17. pii: 5679635. doi: 10.1093/cid/ciz1199.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.